

and the Fondo Europeo de Desarrollo Regional (FEDER), A. Martinez-Aran: None Declared, E. Vieta Grant / Research support from: Spanish Ministry of Science and Innovation (PI18/00805, PI21/00787) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357; the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907 and EU.3.1.3. Treating and managing disease: Grant No 945151), B. Sole: None Declared

## EPP0556

### Lithium management around delivery: a retrospective observational cohort study

M. L. Imaz Gurruchaga<sup>1\*</sup>, M. Torra Santamaria<sup>2</sup>, K. Langohr<sup>3</sup> and R. Martin-Santos<sup>4</sup>

<sup>1</sup>Unit of Perinatal Mental Health Clinic-BCN; <sup>2</sup>Pharmacology and Toxicology Laboratory, Hospital Clinic; <sup>3</sup>Department of Statistics and Operational Research, Universitat Politècnica de Catalunya and <sup>4</sup>Psychiatry and Psychology, Hospital Clinic, Barcelona, Spain

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.673

**Introduction:** During the perinatal period lithium is proven effective as maintenance therapy and to prevent postpartum psychosis. Pregnancy affects all aspects of kidney physiology altering the pharmacokinetics of lithium. To minimize the risk of both maternal and neonatal complications around delivery, several authors have provided clinical advice on lithium dosing around delivery: decreasing dose by 30-50%, suspend lithium therapy 24-48 hours before scheduled cesarean section or induced delivery or even discontinuing lithium after first signs of labour.

**Objectives:** To evaluate the validity of these recommendations by investigating 1) maternal lithium serum concentrations changes around delivery, 2) the lithium transplacental passage at delivery and 3) the association between neonatal lithium serum concentration at delivery and neonatal outcomes.

**Methods:** Psychopathologically stable women with a singleton pregnancy (n=66) who used lithium around delivery, were included in this retrospective observational cohort study (HCB/2020/1305). All women were advised to suspend lithium administration at the onset of labour in the event spontaneous deliveries. Study date: demographic, psychiatric, obstetric and neonatal outcomes for each mother-infant pair obtained from the hospital medical records. Lithium serum concentrations were determined by means of an AVL 9180 electrolyte analyzer based on the ion-selective electrode (ISE) measurement principle. Limit of quantification (LoQ) was 0.20 mEq/L.

**Results:** The most common psychiatric diagnosis was a bipolar disorder type I (n=54, 90%). Forty mothers (61%) were on lithium monotherapy. Mean (SD) umbilical cord and intrapartum maternal lithium serum concentration was 0.59 (0.13) mEq/L and 0.55 (0.13) mEq/L respectively. There was a strong positive correlation

between umbilical cord and maternal lithium serum concentrations (Pearson correlation coefficient 0.95 (95%IC: 0.91,0.97). In a subsample (N=22) a paired t test indicates that the maternal serum lithium concentrations at delivery were significantly lower (mean difference=0.19 mEq/L, 95%CI=0.13-0.25) than those during obtained the day before delivery hospitalization, after a mean (SD) of 31.29 ( $\pm$ 11.92) hours (SD=11.92) have elapsed since the taking the last dose of lithium prior to delivery. Four women (6%) relapsed early postpartum. There were no significant differences between lithium monotherapy (N=18/40) and polytherapy (N=11/26) groups with regard to acute neonatal complications (p>0.05). The only acute neonatal complication associated to umbilical cord lithium serum concentration was hypotonia [0.712 (0.298) vs. 0.534 (0.214) (F=5.065; df=1,60; p=0.028)].

**Conclusions:** When lithium is used around delivery, maternal and neonatal well-being can be maximized by maintaining maternal serum lithium concentrations at the minimal effective level and discontinuing briefly when presenting to hospital for delivery.

**Disclosure of Interest:** None Declared

## EPP0557

### Cortisol awakening response in bipolar patients with comorbid type 2 diabetes mellitus

M. Battipaglia<sup>1\*</sup>, N. Attianese<sup>1</sup>, S. Donato<sup>1</sup>, R. Ceres<sup>1</sup>, R. Cerra<sup>1</sup>, A. M. Monteleone<sup>1</sup>, P. Monteleone<sup>2</sup> and G. Cascino<sup>2</sup>

<sup>1</sup>University of Campania "L. Vanvitelli", Naples and <sup>2</sup>University of Salerno, Salerno, Italy

\*Corresponding author.

doi: 10.1192/j.eurpsy.2024.674

**Introduction:** Bipolar Disorder (BD) is a severely debilitating psychiatric disorder with high rates of morbidity and mortality, and patients with BD have a 10-year reduction in their life expectancy. Bipolar disorder (BD) is frequently associated with type 2 diabetes mellitus (T2DM). BD patients with comorbid T2DM have been shown to have three times higher odds of a chronic course and rapid cycling and are more likely to present worse outcomes to treatment with lithium and/or other mood stabilisers when compared to BD patients without IGM (impaired glucose metabolism).

**Objectives:** The functioning of the hypothalamic-pituitary-adrenal (HPA) axis has been never investigated in BD with respect to the glucose metabolic status. Therefore, we assessed the cortisol awakening response (CAR) in bipolar patients with or without comorbid T2DM.

**Methods:** Twenty euglycemic bipolar patients [12 males and eight females; mean age ( $\pm$ SD): 47.4  $\pm$  14.4 years; mean ( $\pm$ SD) duration of illness: 18.3  $\pm$  12.1 years], 16 BD patients with T2DM [11 males and five females; mean age ( $\pm$ SD): 63.6  $\pm$  12.8 years; mean ( $\pm$ SD) duration of bipolar illness: 17.1  $\pm$  10.8 years; mean ( $\pm$ SD) duration of T2DM: 5.2  $\pm$  5.3 years], 18 healthy subjects [seven males and 11 females; mean age ( $\pm$ SD): 45.0  $\pm$  12.1 years] and 12 non-psychiatric subjects with T2DM [eight males and four females; mean age ( $\pm$ SD): 56.7  $\pm$  11.2 years; mean ( $\pm$ SD) duration of